Showing results (1181-1190 of 1,205) with videos related to

Sort By:
Pageof 121
Frontiers in Psychiatry|June 7, 2022
Add-On MEmaNtine to Dopamine Antagonism to Improve Negative Symptoms at First Psychosis- the AMEND Trial ProtocolKatharina O Sandström, Olga B Baltzersen, Anouk Marsman, et al.
Leukemia|May 29, 2021
Lymphoma and multiple myeloma in cohorts of persons exposed to ionising radiation at a young ageMark P Little, Richard Wakeford, Lydia B Zablotska, et al.
British Journal of Cancer|August 18, 2023
Radiation exposure and leukaemia risk among cohorts of persons exposed to low and moderate doses of external ionising radiation in childhoodMark P Little, Richard Wakeford, Lydia B Zablotska, et al.
Bioorganic & Medicinal Chemistry Letters|February 5, 2008
Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonistsYounong Yu, Michael P Dwyer, Jianping Chao, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2009
Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitorsEric J Gilbert, Guowei Zhou, Michael K C Wong, et al.
Bioorganic & Medicinal Chemistry Letters|April 5, 2011
2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitorsChaoyang Dai, Dansu Li, Janeta Popovici-Muller, et al.
Magnetic Resonance in Medicine|November 10, 2023
Diffusion-weighted MR spectroscopy: Consensus, recommendations, and resources from acquisition to modelingClémence Ligneul, Chloé Najac, André Döring, et al.
Thrombosis Update|April 15, 2024
Biomarkers of thromboinflammation correlate to COVID-19 infection and admission status in emergency department patientsJulie Goswami, Taleen A MacArthur, Meera Sridharan, et al.
Bioorganic & Medicinal Chemistry Letters|July 29, 2010
Biaryl substituted hydantoin compounds as TACE inhibitorsWensheng Yu, Ling Tong, Seong Heon Kim, et al.
Journal of Medicinal Chemistry|December 22, 2006
Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonistMichael P Dwyer, Younong Yu, Jianping Chao, et al.
Pageof 121